Qiagen N.V. (QIAGEN) is a global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life.
The company’s Sample technologies isolate and process DNA (deoxyribonucleic acid), RNA (ribonucleic acid) and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find...
Qiagen N.V. (QIAGEN) is a global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life.
The company’s Sample technologies isolate and process DNA (deoxyribonucleic acid), RNA (ribonucleic acid) and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. The company serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare.
As molecular biology and genomic knowledge has grown to influence many areas of daily life, the company has expanded to serve the full spectrum of market needs while developing new instruments, consumables and digital solutions, partnering with researchers and pharmaceutical companies, and acquiring companies and technologies that best complement the company’s portfolio. The company continues to accelerate its portfolio growth and increase the company’s efficiency and effectiveness while also enhancing its customer experience, the company’s corporate citizenship and its position as an employer of choice.
The company’s strategy is anchored by a commitment to deliver solid profitable growth by focusing the company’s resources on a group of Pillars that represented approximately 70% of sales in 2024. The Pillars involve three product groups where QIAGEN is developing leadership positions: the digital PCR (Polymerase Chain Reaction) platform QIAcuity, the clinical PCR syndromic testing solution QIAstat-Dx and the QIAGEN Digital Insights portfolio of bioinformatics solutions for improved analysis and interpretation of complex genomic data.
Additionally, two Pillars involve product groups where QIAGEN has strong top positions and where the company wants to consolidate its leadership: Sample technologies that are used to gain access to DNA and RNA from a biological sample and the QuantiFERON technology platform for latent disease detection, best known for its use in detecting tuberculosis (TB).
QIAGEN Products
The company’s leadership in molecular research and testing solutions leverages the company’s product portfolio across a wide range of applications. These are grouped into two main categories:
Consumables and related revenues involve the company’s consumables kits, bioinformatics solutions, royalties, co-development milestone payments and services (89% of total net sales in 2024); and
Instruments and related services and contracts (11% of total net sales in 2024).
QIAGEN Product Groups
Sample Technologies
Sample technologies represent one of the company’s Pillars and includes products involved in the first step of any molecular lab process.
The company’s broad portfolio of Sample technologies includes consumables and instruments used in sample collection, stabilization, storage, purification and quality control. Some of the company’s consumables are designed to run on the company’s instruments, while others are universal kits designed for use with any molecular-testing platform. These products are used in research and applied testing (forensics/human identification and food safety) in laboratories, as well as clinical testing.
Diagnostic Solutions
Diagnostic solutions include the company’s molecular testing platforms and consumables covering two of the company’s Pillars with QuantiFERON and QIAstat-Dx, as well as Precision Diagnostics which involves companion diagnostic co-development revenues from projects with pharmaceutical companies, regulated assays and solutions for laboratory developed tests. Additional areas include Oncology and Sexual & Reproductive Health for detection of various diseases and for other laboratory processes.
PCR / Nucleic Acid Amplification
PCR / Nucleic Acid Amplification involves the company’s research and applied PCR solutions and components. The product group includes another of the company’s Pillars, QIAcuity. The company offers optimized solutions for end-point PCR, quantitative PCR and digital PCR. The company’s kits, assays, instruments and accessories amplify and detect targets and streamline workflow for virtually any application.
Genomics / NGS
This product group includes the company’s universal NGS (next-generation sequencing) solutions for use with any NGS sequencer as well as the full bioinformatics portfolio offered by QIAGEN Digital Insights, which also represents one of the company’s Pillars.
Other
Revenues from various sources, including protein biology products, royalties, intellectual property and freight charges.
Principal Markets
The company sells its products to more than 500,000 customers in two broad customer groups: Molecular Diagnostics (clinical testing) and Life Sciences (academia, pharmaceutical R&D and applied testing).
Molecular Diagnostics
The molecular diagnostics market includes healthcare providers engaged in many aspects of patient care that require accurate diagnoses and insights to guide treatment decisions in oncology, infectious diseases and immune monitoring.
The company offers one of the broadest portfolios of molecular technologies for healthcare. The success of molecular testing in healthcare depends on the ability to accurately analyze purified nucleic acid samples from sources such as blood, tissue, body fluids and stool. Automated systems process tests reliably and efficiently, often handling hundreds of samples simultaneously. The company’s range of assays for diseases and biomarkers speeds up and simplifies laboratory workflow and standardizes lab procedures.
Molecular testing is the most dynamic segment of the global in vitro diagnostics market. The pandemic has demonstrated the value of molecular testing in healthcare, and the company expects the market to provide significant growth opportunities.
The company has built a position as a preferred partner to co-develop companion diagnostics paired with targeted drugs and have created a rich pipeline of molecular tests that are transforming the treatment of cancer and other diseases. The company has more than 30 master collaboration agreements with pharmaceutical industry customers, some with multiple co-development projects. In 2024, the company continued to expand on these partnerships with new agreements, for example, a collaboration with Eli Lilly to develop an IVD panel for detecting APOE genotypes. The company also expanded its partnership with AstraZeneca to develop and commercialize companion diagnostics for complex chronic diseases based on the company’s QIAstat-Dx platform. Additionally, the company entered into a master collaboration agreement with Myriad to develop lab-developed and distributable kit-based companion diagnostics in oncology. Companion diagnostics move through clinical trials and regulatory approvals, along with the paired drugs, to commercialization and marketing to healthcare providers.
Life Sciences
The Life Sciences market includes governments and biotechnology companies, where researchers and scientists are using molecular testing technologies to advance scientific knowledge in the pursuit of new breakthroughs that can lead to new medicines and diagnostics for use in clinical healthcare. This market also includes the use of molecular testing technologies for applied applications, in particular for forensics as well as food and veterinary testing. These customers are all often served by public funding and R&D budgets within pharmaceutical companies.
The company partners with customers across diverse disciplines in academia and industry, providing sample technologies, assay technologies, bioinformatics and services to universities and institutes, pharmaceutical and biotech companies, governments and law enforcement agencies.
The company provides Sample to Insight solutions to academic and research institutions around the world. The company focuses on enabling researchers to use high-quality technologies to generate reliable, fast, highly reproducible results, sometimes replacing time-consuming traditional or in-house methods. The company often partners with leading institutions on research projects and develop customized solutions, such as NGS panels for the sequencing of multiple gene targets.
The company is a global leader in solutions for governments and industry, particularly in forensic testing and human identification. The value of genetic ‘fingerprinting’ has been proven in criminal investigations and examinations of paternity or ancestry, as well as in food safety. The company provides sample collection and analytical solutions for law enforcement and human identification labs, as well as advanced technologies for studies of microbiomes and their effect on health and the environment.
The company has deep relationships with pharmaceutical and biotechnology companies. Drug discovery and development, as well as translational research efforts increasingly employ genomic information, both to guide research in diseases and to differentiate patient populations that are most likely to respond to particular therapies. The company estimates that about half of its sales to these companies supports research while the other half supports clinical development, including stratification of patient populations based on genetic information. Also, QIAGEN Digital Insights solutions are widely used to guide pharmaceutical research and treatment options.
Geographical Information
The company sells its products in more than 170 countries.
Seasonality
Historically, a portion of the company’s sales has been to researchers, universities, government laboratories and private foundations whose funding is dependent upon grants from government agencies, such as the National Institutes of Health and similar bodies. Additionally, the company has customers who are active in the diagnostics testing market, and sales to these customers fluctuate to the extent that their activities are impacted by public health concerns.
Sales and Marketing
The company markets its products primarily through subsidiaries in markets with the greatest sales potential in the Americas, Europe, Australia and Asia. Experienced marketing and sales staff, many of them scientists with academic degrees in molecular biology or related areas, sell the company’s products and support the company’s customers. Business managers oversee key accounts to ensure that the company serves customers’ commercial needs, such as procurement processes, financing, data on costs and the value of the company’s systems, while maintaining collaborative relationships. In many markets, the company has specialized independent distributors and importers.
The company’s marketing strategy focuses on providing differentiated, high-quality products across the value chain from Sample to Insight, integrating components into end-to-end solutions when possible and enhancing relationships with a commitment to technical excellence and customer service. The company’s omni-channel approach seeks to engage customers through their preferred channels - online, by phone or in person - and to optimize investment in different customer types.
The company continues to drive the growth of its digital marketing channels – including the company’s website at www.qiagen.com, product-specific sites and social media. Since the onset of the pandemic, there has been an increase in virtual events and use of digital sales channels. The company has likewise increased the activities in digital marketing to adapt to these market changes, such as installing an in-house studio to facilitate creation of video content and live virtual events.
The company’s eCommerce team works with clients to provide automated processes supporting a variety of electronic transactions and all major eProcurement systems.My QIAGEN is an easy-to-use self-service portal that is personalized to the company’s customers' needs and enables customers to manage different activities in one central place. Customers can now easily reorder products, place bulk orders, apply quotes to their cart and track their order status. Functionality in the dashboard allows customers to monitor their instrument use and view the status of licenses and service agreements. Additionally, customers can access the company’s exclusive content and services, such as webinars, handbooks and other documents.
The company’s GeneGlobe Design & Analysis Hub (www.geneglobe.com) is a valuable outreach to scientists in pharma and academia, enabling researchers to search and order from approximately 25 million pre-designed and custom PCR assay kits, NGS assay panels and other products. The new hub brings next-level experiment planning, execution and follow-up to life science researchers, linking the company’s QIAGEN Digital Insights solutions with ordering of assays to accelerate research.
The company uses a range of tools to provide customers with direct access to technical support, inform them of new product offerings and enhance the company’s reputation for technical excellence, high-quality products and commitment to service. For example, the company’s technical service support allows existing or potential customers to discuss a wide range of questions about the company’s products and molecular biology procedures, online or via phone, with Ph.D. and M.Sc. scientists at QIAGEN. Frequent communication with customers enables the company to identify market needs, learn of new developments and opportunities, and respond with new products.
The company also distributes publications, including the company’s catalog, to existing and potential customers worldwide, providing new product information, updates and articles about existing and new applications. In addition, the company holds numerous scientific seminars at clinical, academic and industrial research institutes worldwide and at major scientific and clinical meetings. The company conducts direct marketing campaigns to announce new products and special promotions, and the company offers personalized electronic newsletters and webinars highlighting molecular biology applications.
For laboratories that frequently rely on the company’s consumables, the QIAstock program maintains inventory on-site to keep up with their requirements. QIAGEN representatives make regular visits to replenish the stock and help with other needs, and the company is automating this process with digital technologies. Easy-to-use digital ordering, inventory monitoring and customer-driven changes make QIAstock an efficient system for providing ready access to the company’s products for the hundreds of customers worldwide who use this program.
Intellectual Property, Proprietary Rights and Licenses
As of December 31, 2024, the company owned 282 issued patents in the United States, 229 issued patents in Germany, and 1,615 issued patents in other major industrialized countries. The company had 346 pending patent applications. The company’s policy is to file patent applications in Western Europe, the United States and Japan.
Research and Development
For the year ended December 31, 2024, the company’s research and development expenses were $193.5 million.
Government Regulations
The company is subject to a variety of laws and regulations in the European Union, the United States and other countries.
The company has implemented the requirements set forth by the General Data Protection Regulation (GDPR), which took effect on May 25, 2018. GDPR and other EU data privacy and security laws impact the company’s business either directly or indirectly.
Some of the company’s products are sold for research purposes in the United States, and labeled ‘For Research Use Only’ (RUO) or ‘for molecular biology applications’.
The company’s Redwood City entity serves in some cases as a Business Associate to customers who are subject to the Health Insurance Portability and Accountability Act of 1996 (HIPAA) regulations. The company is subject to prosecution and/or administrative enforcement and increased civil and criminal penalties for non-compliance, including a four-tiered system of monetary penalties adopted under the Health Information Technology for Economic and Clinical Health Act ((HITECH). The company is also subject to enforcement by state attorneys general who were given authority to enforce HIPAA under HITECH.
The company has an established quality system, including standard manufacturing and documentation procedures, intended to ensure that products are produced and tested in accordance with the FDA's Quality System Regulations, which impose current Good Manufacturing Practice (cGMP) requirements.
History
QIAGEN N.V. was founded in 1984.
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.
